Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ

22.88

+0.0903(+0.40%)

Updated at June 10 03:09PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Emil D. Kakkis	Founder, President, Chief Executive Officer & Director	1.19M	1960
Dennis Karl Huang	Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations	331,330	1965
Karah Herdman Parschauer	Chief Legal Officer & Executive Vice President of Corporate Affairs	819,872	1978
Howard Horn	Executive Vice President of Corporate Strategy & Chief Financial Officer	846,010	1979
Eric Crombez	Chief Medical Officer & Executive Vice President	882,356	1973
John Richard Pinion	Chief Quality Operations Officer & Executive Vice President of Translational Sciences	923,934	1966
Erik Harris	Executive Vice President & Chief Commercial Officer	925,255	1970
Ernie W. Meyer	Chief Human Resources Officer & Executive Vice President	0	1965
Theodore A. Huizenga	Senior Vice President, Corporate Controller & Principal Accounting Officer	0	1971
Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	0	1965

Name

Title

Pay

Year Born

Emil D. Kakkis

Founder, President, Chief Executive Officer & Director

1.19M

1960

Dennis Karl Huang

Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations

331,330

1965

Karah Herdman Parschauer

Chief Legal Officer & Executive Vice President of Corporate Affairs

819,872

1978

Howard Horn

Executive Vice President of Corporate Strategy & Chief Financial Officer

846,010

1979

Eric Crombez

Chief Medical Officer & Executive Vice President

882,356

1973

John Richard Pinion

Chief Quality Operations Officer & Executive Vice President of Translational Sciences

923,934

1966

Erik Harris

Executive Vice President & Chief Commercial Officer

925,255

1970

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

1965

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

1971

Vimal Srivastava

Senior Vice President of Business Development & Alliance Management

1965

Description

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.